Press Release
« Back
TG Therapeutics, Inc. Announces Presentation of Pre-Clinical Data on the Combination of TG-1101 and TGR-1202 at the International Conference on Malignant Lymphoma, Lugano, Switzerland
Jun 19, 2013
The presentation, entitled "Novel PI3K Delta Inhibitors Demonstrated Marked Cytotoxicity in T Cell Lymphoma Models and Were Synergistic with A Novel Anti-CD20 mAb, Ublituximab, in Lymphoma Models," highlighted the combination of TG-1101, the Company's glycoengineered, third generation anti-CD20 monoclonal antibody, in combination with TGR-1202, the Company's next generation PI3K delta inhibitor. The research was conducted by
A copy of the presentation is available at http://ir.tgtherapeutics.com/events.cfm.
ABOUT
Cautionary Statement
Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for TG-1101 and TGR-1202 may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101 and TGR-1202; the risk that early clinical results that supported our decision to move forward into expansion cohorts will not be reproduced once additional patients are treated with TG-1101; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the
data produced from prior pre-clinical and clinical trials; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the
TGTX - G
CONTACT:Source:Jenna Bosco Director- Investor RelationsTG Therapeutics, Inc. Telephone: 212.554.4484 Email: ir@tgtxinc.com
News Provided by Acquire Media